Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Below averageWe are a commercial-stage biopharmaceutical company advancing innovative cancer therapies. We currently have two commercially approved medicines, Revuforj® (revumenib) and Niktimvo (axatilimab-csfr), and a robust slate of clinical development programs designed to unlock the full potential of our first two products. Revuforj is our first-in-class menin inhibitor that was approved by the U.S. Food and Drug Administration, or FDA, in November 2024 for the treatment of relapsed or refractory, or R/R, acute leukemia with a lysine methyltransferase 2A gene, or KMT2A, translocation in adult and pediatric patients one year old and older.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Syndax Pharmaceuticals, Inc. (SNDX) reported revenue of $65M in Q1 2026 (quarter ended Mar 31, 2026), up 224% from the same quarter a year earlier. That came with net loss of $43M. For the full year FY2025, revenue was $172M (+628% year on year) and net income −$285M.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.